Exploring Early Ibrutinib Intervention in High-Risk CLL

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.